Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Intocell Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. This distribution suggests that the company's current patenting activity covers different technical or procedural aspects within the broader biotechnology and pharmaceutical field. The involvement of 2 distinct art units means that the company must be prepared for different procedural nuances and examination standards.
STONEBRAKER, ALYSSA RAE is identified as the busiest examiner for this portfolio, with 1 pending office action currently assigned. Since there are 2 distinct examiners for the 2 pending office actions, each examiner handles 1 case. This requires the company to manage two different examination styles and sets of feedback simultaneously. The 1 pending office action assigned to Stonebraker represents a specific point of contact for the company's prosecution strategy in this sector.
Practitioners should monitor both examiners to ensure a consistent overall strategy for the company's intellectual property. While the 2 pending office actions are in the Biotechnology & Pharmaceuticals area, the split across 2 distinct art units may indicate diverse technical applications. Maintaining a cohesive strategy across the 2 distinct art units is essential for a unified patent portfolio. Counsel should address the 1 pending office action assigned to Stonebraker while also managing the other pending matter in this field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STONEBRAKER, ALYSSA RAE | 1 | 58.3% | +49.2% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17781467 | COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION | CHANDRAKUMAR, NIZAL S | 54d |
| 18084739 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | STONEBRAKER, ALYSSA RAE | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18084739 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Dec 20, 2022 |
| 17781467 | COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Final Rejection | 54d | Pending | Jun 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial